ABN AMRO Bank N.V. Sells 469,725 Shares of AbbVie Inc. $ABBV

ABN AMRO Bank N.V. cut its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 54.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 394,664 shares of the company's stock after selling 469,725 shares during the period. AbbVie accounts for approximately 1.3% of ABN AMRO Bank N.V.'s holdings, making the stock its 24th biggest holding. ABN AMRO Bank N.V.'s holdings in AbbVie were worth $99,168,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ABBV. ACT Advisors LLC. lifted its holdings in AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC grew its holdings in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC grew its holdings in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after acquiring an additional 43 shares during the period. Leslie Global Wealth LLC raised its position in shares of AbbVie by 1.5% during the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock valued at $751,000 after acquiring an additional 44 shares during the last quarter. Finally, Bank of Jackson Hole Trust lifted its stake in shares of AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock valued at $1,648,000 after purchasing an additional 44 shares during the period. Institutional investors own 70.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

AbbVie Stock Up 0.4%

Shares of AbbVie stock opened at $265.56 on Wednesday. The stock has a market cap of $469.18 billion, a price-to-earnings ratio of 75.02, a P/E/G ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The company's fifty day moving average is $250.20 and its 200 day moving average is $228.12.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the business earned $2.97 EPS. The business's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's payout ratio is currently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Humira replacement strategy is gaining credibility: second-quarter revenue rose 10.2% to $16.99 billion, led by immunology products and supported by neuroscience. This suggests Skyrizi, Rinvoq and other newer medicines are more than offsetting Humira’s biosimilar-related decline. AbbVie’s Humira Replacement Strategy Is Working
• Positive Sentiment: New lung-cancer data for investigational treatments ABBV-1480, ABBV-706 and Temab-A point to potentially meaningful future growth in oncology. Reported response rates and manageable safety profiles strengthen the case for AbbVie’s longer-term pipeline, though the programs remain dependent on additional clinical results and approvals. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Several investment managers increased their AbbVie holdings, including Convergence Financial, which nearly doubled its position, and Donaldson Capital Management, which modestly raised its stake. These filings provide a supportive institutional signal but are not major earnings catalysts. Convergence Financial Increased Its AbbVie Holdings
• Neutral Sentiment: In comparisons with Eli Lilly, AbbVie offers a more established cash-generating portfolio and attractive pipeline opportunities, while Lilly has stronger headline growth prospects. The debate highlights AbbVie’s balance between income, stability and pipeline execution rather than a clear near-term catalyst. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Second-quarter oncology sales declined 2.4% as Imbruvica continued to weaken. Growth from Venclexta and newer medicines partly offset the pressure, but the result underscores ongoing reliance on successful launches and pipeline products to revive the franchise. How Did AbbVie’s Oncology Sales Hold Up in Q2?

Analysts Set New Price Targets

Several research firms have recently issued reports on ABBV. Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. UBS Group increased their target price on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Monday, July 13th. Citigroup upped their target price on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source